Skip to Content

Study with 3,334 patients validates circulating tumor DNA for genomic sequencing as an alternative to biopsies in mCRPC

The study demonstrated a high correlation between gene mutation changes identified by circulating tumor DNA (ctDNA) and biopsy-based genomic sequencing. In addition, liquid biopsies were better at identifying acquired resistance mechanisms than tissue biopsies.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top